Results 21 to 30 of about 19,083 (252)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis

Arthritis Research & Therapy, 2017
Background Biologic disease-modifying antirheumatic drugs (DMARDs) are increasingly used for rheumatoid arthritis (RA) treatment. However, little is known based on contemporary data about the factors associated with DMARDs and patterns of use of biologic
Yinzhu Jin, Rishi J. Desai, Jun Liu, Nam-Kyong Choi, Seoyoung C. Kim   +4 more
doaj   +1 more source

Frequency and Effective Factors on Discontinuation of Treatment in Patients with Inflammatory Rheumatic Diseases

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Treatment of rheumatic diseases depends on proper use of medications. The aim of this study was to evaluate the frequency and reasons for discontinuation of drugs in these patients.
Maryam Mobini, Reza Ali Mohammadpour, Mohammad Reza Biabani   +2 more
doaj  

Management of rheumatoid arthritis in Poland – where daily practice might not always meet evidence-based guidelines

Archives of Medical Science, 2019
Introduction International recommendations are intended to help rheumatologists in the effective management of rheumatoid arthritis (RA) through an evidence-based approach.
Bogdan Batko, Mariusz Korkosz, Anna Juś, Piotr Wiland   +3 more
doaj   +1 more source

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study

Arthritis Research & Therapy, 2022
Background To analyse the subsequent clinical course of patients with rheumatoid arthritis (RA) who either continued or discontinued biologic agents after hospitalization for infections.
Yusuke Kashiwado, Chikako Kiyohara, Yasutaka Kimoto, Shuji Nagano, Takuya Sawabe, Kensuke Oryoji, Shinichi Mizuki, Hiroaki Nishizaka, Seiji Yoshizawa, Shigeru Yoshizawa, Tomomi Tsuru, Yasushi Inoue, Naoyasu Ueda, Shun-ichiro Ota, Yasuo Suenaga, Tomoya Miyamura, Yoshifumi Tada, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi   +19 more
doaj   +1 more source

Treatment patterns of biologic disease-modifying anti-rheumatic drugs in juvenile idiopathic arthritis: a population-based study in Korea

Journal of Rheumatic Diseases
Objective: Juvenile idiopathic arthritis (JIA) is the most common chronic arthritis in children, with an unknown cause and prolonged disease course. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have improved outcomes in severe or refractory ...
Jong Gyun Ahn, Min-Taek Lee, Daye Lee, Eun Jeong Min, Dae Chul Jeong   +4 more
doaj   +1 more source

Supplemental Material, Table_S1 - Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database

, 2018
Supplemental Material, Table_S1 for Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database by Yomei Matsuoka, Mamoru Narukawa in Therapeutic Innovation & Regulatory Science
Mamoru Narukawa (5170892), Yomei Matsuoka (5170889)   +1 more
core   +1 more source

Supplemental Material, Table_S2 - Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database

, 2018
Supplemental Material, Table_S2 for Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database by Yomei Matsuoka, Mamoru Narukawa in Therapeutic Innovation & Regulatory Science
Mamoru Narukawa (5170892), Yomei Matsuoka (5170889)   +1 more
core   +1 more source

Influence of biologic and conventional disease-modifying antirheumatic drugs on COVID-19 incidence among rheumatic patients during the first and second wave of the pandemic in Iran

, 2022
INTRODUCTION: During the SARS-CoV-2 virus pandemic, immunosuppressive agents in treating chronic disease have become a concern, and rheumatic patients are not an exception.
Mirfeizi, Zahra, Firoozabadi, Mona, Zhaleh Shariati-Sarabi, Shariati-Sarabi, Zhaleh, Zahra Mirfeizi, Dadgar Moghadam, Malihe, Hashemzadeh, Kamila, Malihe Dadgar Moghadam, Sahebari, Maryam, Kamila Hashemzadeh, Mona Firoozabadi, Maryam Sahebari   +11 more
core   +1 more source

A short history of anti-rheumatic therapy - VII. Biological agents

Reumatismo, 2011
The introduction of biological agents has been a major turning-point in the treatment of rheumatic diseases, particularly in rheumatoid arthritis. This review describes the principle milestones that have led, through the knowledge of the structure and ...
B. Gatto, P. Marson, G. Pasero
doaj   +1 more source

Supplemental Material, Table_S3 - Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database

, 2018
Supplemental Material, Table_S3 for Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report Database by Yomei Matsuoka, Mamoru Narukawa in Therapeutic Innovation & Regulatory Science
Mamoru Narukawa (5170892), Yomei Matsuoka (5170889)   +1 more
core   +1 more source